Well my reason for rejecting "never" is not based on the science as much as on the economics.
Teva can see a $250m/yr product if they get approval. That means it would be worthwhile for them to spend $500m to get it approved. I have to believe that given Teva's overall resources, $500m and the FDA roadmap can achieve approval.
Market Data 
Markets 
AI
